An ongoing dialogue on HIV/AIDS, infectious diseases,
June 30th, 2023
The Yin and the Yang of Cabotegravir-Rilpivirine: Part One, the Good News
Long-acting cabotegravir-rilpivirine (CAB-RPV) is the biggest advance in HIV therapeutics in years. It’s also creating quite the challenge for ID and HIV clinicians, which makes its availability a fascinating example of the importance of education, patient communication, and shared decision-making. This post will be the good news about this groundbreaking treatment; in the next post, […]
June 15th, 2023
Clinical Teaching at the 99.9th Percentile: Dr. Martin (Marty) Samuels
One of the true joys of practicing at academic medical centers is working alongside great clinical teachers. No one exemplified this talented group better than Dr. Martin (Marty) Samuels, former chief of neurology at Brigham and Women’s Hospital (where I work), and professor of neurology at Harvard Medical School. He was quite simply the best […]
June 8th, 2023
Fifteen Years Later, Why I’m Still Writing This
Seems like just yesterday that my wonderful editors at NEJM Journal Watch helped me write a piece marking this site’s 10-year anniversary. But no — that was 5 years ago. Yikes. Let’s see, what happened since the spring of 2018 that is relevant to this place: 216 posts. According to our crack research team, that’s […]
June 2nd, 2023
Continued Activity of NRTIs Despite Resistance Is a Real Thing
In our last post, we reviewed a case of a person with longstanding HIV with extensive multi-class resistance, but now a decade of viral suppression. They’re currently on an HIV treatment regimen of fully active raltegravir, partially active etravirine, and barely active (or not active at all!) darunavir. There are no NRTIs in the regimen, […]
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.